High-grade serous carcinoma
Aggressive ovarian cancer often originating in the Fallopian tube.
Last updated
High-grade serous carcinoma (HGSC) is a tumour arising from the serous epithelial layer in the abdominopelvic cavity, most commonly found in the ovary. It constitutes the majority of ovarian cancer cases and has the lowest survival rates among them. HGSC is now understood to originate in the Fallopian tube epithelium rather than the ovarian surface, and it is more invasive than low-grade serous carcinoma.
Quick Facts
- Age-specific incidence rate plateau
- approximately 20 cases per 100,000 women
Facts from the source article.
Risk factors
The 'incessant ovulation' theory links a higher number of ovulatory cycles to increased ovarian cancer risk, with protective effects observed from pregnancy, parity, breastfeeding, and oral contraceptive use. Ovulation is accepted as the cause of ovarian cortical inclusion cysts, which are precursor lesions of serous carcinomas. Conversely, menopausal hormone therapy shows a temporal association with HGSC incidence, and polycystic ovarian syndrome doubles the risk.
Endometriosis is not associated with HGSC. Over 20% of ovarian cancers have hereditary origins, most featuring BRCA gene mutations; BRCA1 mutations confer a 40-50% lifetime risk and BRCA2 mutations a 10-20% risk, with BRCA2 linked to better outcomes.
A 'p53 signature' in the Fallopian tube epithelium is considered a precursor marker, as TP53 mutations occur in 96% of HGSC cases. Pelvic HGSC shows either complete absence or overexpression of P53, with overexpression associated with better clinical outcome and absence linked to recurrence. A recent mouse model suggests a p53 mutation may induce HGSC arising from the ovary rather than the tube.
Pathophysiology
HGSC is classified as a type II ovarian tumour under the type I/II nomenclature, meaning it develops de novo from tubal or ovarian surface epithelium without characterised precursor lesions within the ovary; this classification is more relevant to research than clinical practice. The serous membrane is a secretory epithelium lining body cavities, and serous carcinoma can occur anywhere on these membranes, though HGSC is generally limited to the peritoneal area.
While previously thought to arise from cortical inclusion cysts of ovarian surface epithelium, the cell origin is now understood to be more complex, with evidence for both intra- and extra-ovarian sites. The common Müllerian origin of the Fallopian tubes, uterus, cervix, and upper vagina has led to the proposal that peritoneal HGSC is a spectrum of a single disease. Determining cell origin is less important for clinical treatment but may aid biomarker discovery.
The specific process of HGSC development may relate to BRCA and p53 mutation status. A 2007 paper notes that tumour origin is typically assigned to the organ with the dominant mass, except for the peritoneum, which is classified as primary only if no candidate origin is found in the endometrium, tube, or ovary.
Diagnosis
Symptoms of HGSC include persistent bloating, postmenopausal bleeding, and appetite loss. Transvaginal ultrasonography and CA125 level analysis help assess potential malignancy of pelvic masses. Surgical staging via laparoscopy examines the abdominal cavity and lymph nodes, with tissue biopsies taken for histological analysis, which is required for actual diagnosis. Histologically, serous carcinoma is suspected when glands fuse with intricate papillae featuring epithelial tufting, solid nests surrounded by a space, and irregular slit-like spaces.
Necrosis and giant tumour cells are common in HGSC but absent in low-grade serous carcinoma, while psammoma bodies are more frequent in low-grade disease. TP53 expression is assessed for mutations, overexpression, or absence, all common in HGSC. Distinction from high-grade endometrioid carcinoma is not always possible. Cadherin expression profiling may indicate progression.
Treatment
Cytoreductive debulking surgery is often performed before chemotherapy to reduce tumour mass and the number of chemotherapy cycles needed. Typical chemotherapy consists of six cycles of intraperitoneally delivered platinum-based agents such as carboplatin, with CA125 levels used to monitor response. Between 20% and 30% of patients relapse within six months. PARP inhibitors are another treatment option, with BRCA1/2 mutation carriers being the most responsive.
Did You Know?
- Tubal ligation is a less invasive prophylactic treatment shown to significantly reduce the risk of HGSC.
- A racial disparity exists between black and white women in the US, where black women experience a higher mortality risk from ovarian cancer.
- Since 1975, survival rates for ovarian cancer have steadily improved with a mean decrease of 51% by 2006 of risk of death from ovarian cancer for an advanced stage tumour.
More in Gynaecology
Sources
Compiled from Wikipedia and the sources listed below. Text from Wikipedia is available under CC BY-SA 4.0; this entry is adapted from it.
- Wikipedia: High-grade serous carcinoma (CC BY-SA 4.0).
- Word definitions: the Codexery glossary, each quoted from its Wikipedia article.
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced